Jatin Rana, MD
Hematology & Oncology · Lansing, MINPI 1699094813
Payments from drug & device makers
What this record shows
Novo Nordisk AS accounts for 60.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,078 and has fallen 91.0% since, to $97 in 2023. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 15 payments — averaging $99.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$903
- Genentech USA, Inc.$165
- Novo Nordisk$125
- E.r. Squibb & Sons, L.L.C.$124
- Lilly USA, LLC$97
- Morphosys, US Inc.$42
- plus $35 from 1 others
Across 7 payments — averaging $1357.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Incyte Corporation$1K
What the payments were for
- Travel & lodging$60841%
- Food & beverage$88259%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 2 | $903 |
| Genentech USA, Inc. | 8 | $165 |
| Novo Nordisk | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $124 |
| Lilly USA, LLC | 1 | $97 |
| Morphosys, US Inc. | 1 | $42 |
| Tesaro, Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,490 in reported general payments places this provider in the 45th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 25 | $384,417 |
| Lenalidomide | 23 | $334,231 |
| OrserduElacestrant Hcl | 13 | $302,313 |
| XareltoRivaroxaban | 20 | $23,396 |
| EliquisApixaban | 26 | $19,618 |
| Anastrozole | 95 | $4,832 |
| Tamoxifen Citrate | 71 | $3,036 |
| Letrozole | 16 | $2,150 |
| Hydroxyurea | 16 | $444 |
| Gabapentin | 13 | $207 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Lansing
- Gordon SrkalovicLansing$167K
- Brittani ThomasLansing$7K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.